NOVONIX Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	5.62	5.85	8.05	6.1	3.89
Revenue Growth (YoY)	-4.05%	-27.32%	32.02%	56.69%	36.57%
Cost of Revenue	2.5	1.77	2.82	1.72	0.81
Gross Profit	3.12	4.08	5.24	4.38	3.08
Selling, General & Admin	45.09	49.08	44.83	39.86	11.67
Depreciation & Amortization Expenses	4.57	4.57	4.74	4.21	1.26
Research & Development	5.67	4.85	5.75	5.1	2.09
Other Operating Expenses	7.35	-	-	4.23	2
Total Operating Expenses	62.68	58.49	55.32	53.4	17.03
Operating Income	-59.57	-54.41	-50.08	-49.03	-13.94
Interest Expense	-11.95	-3.57	-2.86	-1.51	-0.17
Other Non-Operating Income (Expense)	-21.19	-16.75	6.5	-1.32	0.67
Total Non-Operating Income (Expense)	-33.13	-20.31	3.63	-2.83	0.5
Pretax Income	-92.7	-74.72	-46.45	-51.86	-13.45
Provision for Income Taxes	-0.03	-0.1	0.2	-	-
Net Income	-92.73	-74.82	-46.25	-51.86	-13.45
Net Income to Common	-92.73	-74.82	-46.25	-51.86	-13.45
Shares Outstanding (Basic)	170	124	122	116	92
Shares Outstanding (Diluted)	170	124	122	116	92
Shares Change (YoY)	37.20%	1.93%	4.96%	26.80%	169.49%
EPS (Basic)	-0.56	-0.60	-0.36	-0.44	-0.16
EPS (Diluted)	-0.56	-0.60	-0.36	-0.44	-0.16
Shares Outstanding	210.02	141.99	122.18	121.49	101.15
Free Cash Flow	-102.37	-70.3	-55.41	-112.92	-25.58
Free Cash Flow Per Share	-0.60	-0.57	-0.45	-0.97	-0.28
Gross Margin	55.49%	69.76%	65.02%	71.73%	79.18%
Operating Margin	-1060.46%	-929.39%	-621.75%	-803.55%	-358.13%
Profit Margin	-1649.85%	-1274.71%	-579.15%	-850.01%	-345.34%
FCF Margin	-1822.48%	-1200.75%	-687.94%	-1850.76%	-656.86%
EBITDA	-55	-49.84	-45.34	-44.81	-12.68
EBITDA Margin	-979.09%	-851.35%	-562.91%	-734.47%	-325.65%
EBIT	-59.57	-54.41	-50.08	-49.03	-13.94
EBIT Margin	-1060.46%	-929.39%	-621.75%	-803.55%	-358.13%
Effective Tax Rate	0.03%	0.13%	-0.43%	0.00%	0.00%

SEC Filings: 10-K · 10-Q